MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to common...
-$2,836,128
(56.23%↑ Y/Y)
Net (income) loss at
subsidiary attributable to...
-$28,583
(-179.28%↓ Y/Y)
Net loss
-$2,864,711
(55.54%↑ Y/Y)
Loss before income
taxes
-$2,811,235
(56.53%↑ Y/Y)
Income tax (expense)
benefit
$40,256
(277.58%↑ Y/Y)
Equity in loss of
investee
-$13,220
Interest income
$476,748
(42.55%↑ Y/Y)
Product
$40,396,278
Manufactured Product Other
$4,125,153
Operating loss
-$2,791,993
(56.59%↑ Y/Y)
Interest expense
$495,990
(-18.09%↓ Y/Y)
Net revenues
$44,521,431
(17.57%↑ Y/Y)
Total costs and
expenses
$47,313,424
(6.80%↑ Y/Y)
Selling and marketing
$19,098,153
(12.19%↑ Y/Y)
General and
administrative
$11,946,909
(7.37%↑ Y/Y)
Cost of products sold
$6,667,207
(1.23%↑ Y/Y)
Research and development
$5,566,498
(15.58%↑ Y/Y)
Amortization and impairment
$4,034,657
(-15.03%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
CUMBERLAND PHARMACEUTICALS INC (CPIX)
CUMBERLAND PHARMACEUTICALS INC (CPIX)